alea-institute/kl3m-data-sample-004-shuffled huggingface dataset:
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Institute on Drug Abuse Special Emphasis Panel, Therapeutic Communities Research.                    

*Date:*                         July 26, 2001.                    

*Time:*                         9 a.m. to 6 p.m.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         JW Marriott Hotel, 1331 Pennsylvania Avenue, Washington, DC 20004.                    

*Contact Person:*                         Kesinee Nimit, MD, Health Scientist Administrator, Office of Extramural Affairs, National Institute on Drug Abuse, National Institutes of Health, DHHS, 6001 Executive Boulevard, Room 3158, MSC 9547, Bethesda, MD 20891-9547, (301) 435-1432.                    

(Catalogue of Federal Domestic Assistance Program Nos. 93.277, Drug Abuse Scientist Development Award for Clinicians, Scientist Development Awards, and Research Scientist Awards; 93.278, Drug Abuse National Research Service Awards for Research Training; 93.279, Drug Abuse Research Programs, National Institutes of Health, HHS).

Dated: June 12, 2001.

Anna Snouffer,

Acting Director, Office of Federal Advisory Committee Policy.

[FR Doc. 01-15468  Filed 6-19-01; 8:45 am]

BILLING CODE 4140-01-M
Joan MARSH, petitioner, v. UNITED STATES.

No. 16M51.

Supreme Court of the United States

Nov. 14, 2016.

Motion to direct the Clerk to file a petition for writ of certiorari out of time denied.
<TABLE> <S> <C>

<ARTICLE> 5
<LEGEND>
THE FINANCIAL DATA SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED
FROM RIVIANA FOODS INC.'S FORM 10K FOR FISCAL 2000 AND IS QUALIFIED IN ITS
ENTIRETY BY REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<MULTIPLIER> 1,000

<S>                             <C>
<PERIOD-TYPE>                   12-MOS
<FISCAL-YEAR-END>                          JUL-02-2000
<PERIOD-END>                               JUL-02-2000
<CASH>                                           7,414
<SECURITIES>                                     1,582
<RECEIVABLES>                                   40,826
<ALLOWANCES>                                     1,032
<INVENTORY>                                     48,923
<CURRENT-ASSETS>                               107,225
<PP&E>                                         140,035
<DEPRECIATION>                                  53,911
<TOTAL-ASSETS>                                 209,115
<CURRENT-LIABILITIES>                           57,792
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                        15,883
<OTHER-SE>                                     119,048
<TOTAL-LIABILITY-AND-EQUITY>                   209,115
<SALES>                                        435,885
<TOTAL-REVENUES>                               435,885
<CGS>                                          292,780
<TOTAL-COSTS>                                  109,160
<OTHER-EXPENSES>                                 2,308
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                             (1,078)
<INCOME-PRETAX>                                 36,253
<INCOME-TAX>                                    10,855
<INCOME-CONTINUING>                             25,101
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                    25,101
<EPS-BASIC>                                       1.74
<EPS-DILUTED>                                     1.73


</TABLE>
H. Res. 1654 

In the House of Representatives, U. S., 

November 16, 2010. 

Whereas close to 600 colleges and universities in the United 

States and thousands of undergraduate students and faculty pursue undergraduate research every year, providing 

research opportunities that will shape the trajectory of 

students’ lives and careers and researchers’ and institutions’ purpose and contributions to academia and the research enterprise; 

Whereas students and faculty engaged in undergraduate research contribute to research across many disciplines, including arts and humanities, biology, chemistry, health 

sciences, geosciences, mathematics, computer science, 

physics and astronomy, psychology, and social sciences; 

Whereas research at the undergraduate level provides both 

students and faculty members opportunities for improving and assessing the research environment at their institution, develops critical thinking, creativity, problem solving, and intellectual independence, and promotes an innovation-oriented culture; 

Whereas undergraduate research is essential to pushing the 

Nation’s innovation agenda forward by increasing the interest and persistence among young people in the crucial 

science, technology, engineering, and mathematics 

(STEM) disciplines, and to cultivating the interest of 
2 

•HRES 1654 EH 

would-be researchers who pursue a new aspiration of 

graduate education after participating in undergraduate 

research; and 

Whereas the week of April 11, 2011, would be an appropriate 

week to designate as ‘‘Undergraduate Research Week’’: 

Now, therefore, be it 

Resolved, That the House of Representatives— 

(1) supports the designation of ‘‘Undergraduate Research Week’’; 

(2) recognizes the importance of undergraduate research and of providing research opportunities for the 

Nation’s talented youth to cultivate innovative, creative, 

and enterprising young researchers, in collaboration with 

dedicated faculty; 

(3) encourages institutions of higher education, 

Federal agencies, businesses, philanthropic entities, and 

others to support undergraduate research and undergraduate researchers and their faculty mentors; 

(4) encourages opportunities, including through existing programs, for females and underrepresented minorities to participate in undergraduate research; and 
3 

•HRES 1654 EH 

(5) supports the role undergraduate research can 

and does play in crucial research that serves the Nation’s best economic and security interests. 

Attest: 

Clerk.
CONSENT OF INDEPENDENT AUDITORS


We consent to the  incorporation by reference in the  Registration  Statement on
Form S-8 pertaining to the 1995 Key Employee Stock Compensation  Program and the
1995  Directors'  Stock Option Plan of Bank West  Financial  Corporation  of our
report  dated  August  16,  1999,  with  respect to the  consolidated  financial
statements of Bank West Financial  Corporation  incorporated by reference in the
Annual Report on Form 10-K for the year ended June 30, 1999.





                                                /s/Crowe, Chizek and Company LLP
                                                --------------------------------
                                                   Crowe, Chizek and Company LLP

Grand Rapids, Michigan
September 24, 1999
Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### National Institutes of Health

Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting.

The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy.

*Name of Committee:*                         National Human Genome Research Institute Initial Review Group, Ethical, Legal, Social Implications Review Committee.                    

*Date:*                         July 12-13, 2001.                    

*Time:*                         8:00 am to 6:00 pm.                    

*Agenda:*                         To review and evaluate grant applications.                    

*Place:*                         The Hyatt Regency Hotel, 100 Bethesda Metro Center, Bethesda, MD 20814.                    

*Contact Person:*                         Rudy O. Pozzatti, PhD, Scientific Review Administrator, Office of Scientific Review, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD 20892, 301 402-0838.                    

(Catalogue of Federal Domestic Assistance Program Nos. 83.172, Human Genome Research, National Institutes of Health, HHS).

Dated: June 14, 2001.

LaVerne Y. Stringfield,

Director, Office of Federal Advisory Committee Policy.

[FR Doc. 01-15463 Filed 6-19-01; 8:45 am]

BILLING CODE 4140-01-M
Aba David CZEKUS, petitioner, v. W. KNIPP, Warden.

No. 16-5949.

Supreme Court of the United States

Oct. 31, 2016.

Petition for writ of certiorari to the United States Court of Appeals for the Ninth Circuit denied.
Exhibit 32.2


                            CERTIFICATION PURSUANT TO
                             18 U.S.C. SECTION 1350,
                             AS ADOPTED PURSUANT TO
                  SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002


         In connection with the quarterly report of SiriCOMM, Inc. (the
"Company") on Form 10-QSB/A for the period ending December 31, 2005 as filed
with the Securities and Exchange Commission on May 5, 2006 (the "Report"), I, J.
Richard Iler, Chief Financial Officer of the Company, certify, pursuant to 18
U.S.C. ss. 1350, as adopted pursuant to ss. 906 of the Sarbanes-Oxley Act of
2002, that:

         (1)      The Report fully complies with the requirements of section
                  13(a) or 15(d) of the Securities Exchange Act of 1934; and

         (2)      The information contained in the Report fairly presents, in
                  all material respects, the financial condition and result of
                  operations of the Company.



/s/ J. Richard Iler
---------------------------
J. Richard Iler
Chief Financial Officer
May 5, 2006


A signed original of this certification has been provided to the Company and
will be retained by the Company and furnished to the Securities and Exchange
Commission or its staff upon request.
Exhibit ???


                               THIRD AMENDMENT TO
                              THE ENGLOBAL 401 (K)
                                      PLAN

WHEREAS, ENGlobal Engineering, Inc. (the "Employer") adopted a restatement of
the ENGlobal 401(k) Plan (the "Plan"), effective as of October 1, 2005, and
various subsequent amendments; WHEREAS, the Employer has the ability to amend
the Plan pursuant to Section 7.1; and WHEREAS, the Employer now desires to amend
the Plan to include service with WRC Corporation;

NOW, THEREFORE, the Employer hereby amends the Plan in the following respects,
effective as of July 1, 2006

     1.   The following shall be added to Section 1.50: Periods of Service with
          WRC Corporation shall be recognized.

     2.   The following shall be added to Section 1.67: Years of Service with
          WRC Corporation shall be recognized. 3

In all other respects, the terms of this Plan are hereby ratified and confirmed.

IN WITNESS WHEREOF, the Employer has caused this Third Amendment to be executed
in duplicate counterparts, each of which shall be considered as an original, as
of the date indicated below.


                                                  ENGLOBAL ENGINEERING, INC.


                                                  //s// William A. Coskey, CEO


                                                  Date:  October 16, 2006


                                                  Witness: //s// Jean Whitaker
<TABLE> <S> <C>

<ARTICLE> 5
       
<S>                             <C>
<PERIOD-TYPE>                   9-MOS
<FISCAL-YEAR-END>                          JUN-30-1999
<PERIOD-END>                               MAR-31-1999
<CASH>                                           5,932
<SECURITIES>                                         0
<RECEIVABLES>                                    6,787
<ALLOWANCES>                                       509
<INVENTORY>                                      9,653
<CURRENT-ASSETS>                                22,615
<PP&E>                                          31,314
<DEPRECIATION>                                  28,543
<TOTAL-ASSETS>                                  27,910
<CURRENT-LIABILITIES>                           15,199
<BONDS>                                              0
<PREFERRED-MANDATORY>                                0
<PREFERRED>                                          0
<COMMON>                                             3
<OTHER-SE>                                       3,956
<TOTAL-LIABILITY-AND-EQUITY>                    27,910
<SALES>                                         35,775
<TOTAL-REVENUES>                                35,775
<CGS>                                           35,816
<TOTAL-COSTS>                                   35,816
<OTHER-EXPENSES>                                     0
<LOSS-PROVISION>                                     0
<INTEREST-EXPENSE>                               (345)
<INCOME-PRETAX>                               (16,386)
<INCOME-TAX>                                       121
<INCOME-CONTINUING>                                  0
<DISCONTINUED>                                       0
<EXTRAORDINARY>                                      0
<CHANGES>                                            0
<NET-INCOME>                                  (16,507)
<EPS-PRIMARY>                                   (5.51)
<EPS-DILUTED>                                   (5.51)
        

</TABLE>
EXHIBIT 31.2

CERTIFICATIONOF PRINCIPAL FINANCIAL OFFICER

I, Martin P.Moore, certify that:

1.     Ihave reviewed this report on Form 10-Q of Cost-U-Less, Inc.;

2.     Based on my knowledge, this report does not contain any untrue statement of amaterial fact or omit to state a material fact necessary to make the statementsmade, in light of the circumstances under which such statements were made, notmisleading with respect to the period covered by this report;

3.     Based on my knowledge, the financial statements, and other financial informationincluded in this report, fairly present in all material respects the financialcondition, results of operations and cash flows of the registrant as of, andfor, the periods presented in this report;

4.     Theregistrant’s other certifying officer and I are responsible forestablishing and maintaining disclosure controls and procedures (as defined inExchange Act Rules 13a-15(e) and 15d-15(e)) for the registrant and have:

     (a)     Designed such disclosure controls and procedures, or caused such disclosurecontrols and procedures to be designed under our supervision, to ensure thatmaterial information relating to the registrant, including its consolidatedsubsidiaries, is made known to us by others within those entities, particularlyduring the period in which this report is being prepared;

     (b)     Evaluated the effectiveness of the registrant’s disclosure controls andprocedures and presented in this report our conclusions about the effectivenessof the disclosure controls and procedures, as of the end of the period coveredby this report based on such evaluation; and

     (c)     Disclosed in this report any change in the registrant’s internal controlover financial reporting that occurred during the registrant’s most recentfiscal quarter that has materially affected, or is reasonably likely tomaterially affect, the registrant’s internal control over financialreporting; and

5.     Theregistrant’s other certifying officer and I have disclosed, based on ourmost recent evaluation of internal control over financial reporting, to theregistrant’s auditors and the audit committee of the registrant’sboard of directors:

     (a)     All significant deficiencies and material weaknesses in the design or operationof internal control over financial reporting which are reasonably likely toadversely affect the registrant’s ability to record, process, summarize andreport financial information; and

     (b)     Any fraud, whether or not material, that involves management or other employeeswho have a significant role in the registrant’s internal control overfinancial reporting.

Date:  May 11,2004

/s/ Martin P.Moore
----

            COMMISSION REGULATION (EC) No 1843/2004

of 22 October 2004         

amending Regulation (EC) No 751/2004 setting certain operative events for the exchange rate for 2004 for the Czech Republic, Estonia, Cyprus, Latvia, Lithuania, Hungary, Malta, Poland, Slovenia and Slovakia to take account of their accession to the European Union

THE COMMISSION OF THE EUROPEAN COMMUNITIES,

Having regard to the Treaty establishing the European Community,

Having regard to the Treaty of Accession of the Czech Republic, Estonia, Cyprus, Latvia, Lithuania, Hungary, Malta, Poland, Slovenia and Slovakia,

Having regard to the Act of Accession of the Czech Republic, Estonia, Cyprus, Latvia, Lithuania, Hungary, Malta, Poland, Slovenia and Slovakia, and in particular the first paragraph of Article 41 thereof,

Whereas:

HAS ADOPTED THIS REGULATION:

Article 1

The following point (e) is added to the first subparagraph of Article 1 of Regulation (EC) No 751/2004:

Article 2

This Regulation shall enter into force on the day of its publication in the Official Journal of the European Union.

It shall apply from 1 May 2004.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels, 22 October 2004.

For the Commission

Franz FISCHLER            

Member of the Commission

----

(1)OJ L 349, 24.12.1998, p. 36. Regulation as last amended by Regulation (EC) No 1250/2004 (OJ L 237, 8.7.2004, p. 13)

(2)OJ L 270, 21.10.2003, p. 1. Regulation as last amended by Regulation (EC) No 864/2004 (OJ L 161, 30.4.2004, p. 48).

(3)OJ L 100, 17.4.1997, p. 2. Regulation as last amended by Regulation (EC) No 1135/2001 (OJ L 154, 9.6.2001, p. 9).

(4)OJ L 118, 23.4.2004, p. 19.

----
Exhibit 10.2



PLX TECHNOLOGY, INC.
2004 BONUS AND DEFERRED COMPENSATION PLAN
(Established as of January 1, 2004)

1. Introduction
2. Definitions
3. "Cause" means (i) conviction of a felony or a crime of
moral turpitude; (ii) misconduct that results in harm to the Company; (iii)
material failure to perform assigned duties; or (iv) willful disregard of lawful
instructions from the chief executive officer of the Company orthe Board
of Directors relating to the business of the Company or any of its
affiliates.
4. "Code" means the Internal Revenue Code of 1986, as
amended.
5. "Committee" means the Compensation Committee of the
Company's Board of Directors.
6. "Company" means PLX Technology, Inc., a Delaware
corporation.
7. "Disability" means the Participant's inability to properly
perform his or her employment duties by reason of any medically determinable
physical or mental impairment which can be expected to result in death or which
has lasted or can be expected to last for a continuous period of not less than
twelve (12) months.
8. "Eligible Employee" means each employee who is eligible for
the plan as designated by the Committee as set forth in approved minutes.
9. "ERISA" means the Employee Retirement Income Security Act
of 1974, as amended.
10. "Net Pro Forma Operating Income" means the Company's pro
forma operating income for 2004, as reported in its earnings release for its
fiscal year ending December 31, 2004, calculated after the payment of all
bonuses.
11. "Normal Retirement Age" means age sixty (60).
12. "Participant" means each Eligible Employee who is
designated from time to time by the Committee in writing.
13. "Plan" means the PLX Technology, Inc. 2004 Bonus and
Deferred Compensation Plan, as set forth in this document and as hereafter
amended.
14. "Plan Year" means the calendar year.
15. "Retirement" means the termination of employment after
Normal Retirement Age.
16. Bonus Amount
17. Calculation of Bonus Amount
18. Interest on Bonus Amount
19. Payment of Bonus
20. Timing and Form of Payment
21. Distribution in the Event of Retirement, Disability or Termination
without Cause
22. Forfeiture
23. Timing of Distribution to a Beneficiary
24. Beneficiary Designation
25. Withholding
26. Administration
27. Amendment or Termination
28. Benefits Upon Plan Termination
29. Claims Procedure
30. Appeal Procedure
31. Source of Payments
32. Inalienability
33. Applicable Law
34. Severability
35. Status of Plan as ERISA "Top Hat" Plan
36. No Right of Continued Employment

IN WITNESS WHEREOF, PLX Technology, Inc., by its duly authorized officer, has
executed the Plan on the day and year first above written.

PLX TECHNOLOGY, INC.

/s/ Michael J. Salameh	   Michael J. Salameh
   Chief Executive Officer